(19)
(11) EP 4 021 912 A1

(12)

(43) Date of publication:
06.07.2022 Bulletin 2022/27

(21) Application number: 20857153.9

(22) Date of filing: 28.08.2020
(51) International Patent Classification (IPC): 
C07F 9/6558(2006.01)
A61K 31/675(2006.01)
C07D 401/06(2006.01)
A61K 31/4439(2006.01)
A61P 35/00(2006.01)
C07D 401/14(2006.01)
(52) Cooperative Patent Classification (CPC):
A61P 35/00; C07D 401/06; C07D 401/14; C07F 9/65583; C07D 405/12
(86) International application number:
PCT/CA2020/051177
(87) International publication number:
WO 2021/035360 (04.03.2021 Gazette 2021/09)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 30.08.2019 CN 201910817505
30.08.2019 CN 201910818675
30.08.2019 CN 201910818779
25.03.2020 US 202062994364 P

(71) Applicant: Risen (Suzhou) Pharma Tech Co., Ltd.
Suzhou, Jiangsu 215000 (CN)

(72) Inventors:
  • LU, Jiasheng
    Shanghai 201702 (CN)
  • GU, Jiamin
    Suzhou, Jiangsu 215000 (CN)
  • CHEN, Gang
    Suzhou, Jiangsu 215000 (CN)
  • ZHANG, Qiguo
    Suzhou, Jiangsu 215000 (CN)
  • SUN, Chengyong
    Suzhou, Jiangsu 215000 (CN)
  • KONG, Xianqi
    Québec H9B 3J7 (CA)

(74) Representative: Høiberg P/S 
Adelgade 12
1304 Copenhagen K
1304 Copenhagen K (DK)

   


(54) PRODRUGS OF THE TYROSINE KINASE INHIBITOR FOR TREATING CANCER